Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 400.24M shares rose 10.5% year over year, ahead of the +6.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 10.1% from the prior quarter. Over 3 fiscal years it compounded at +29.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.5% holds above the trailing-twelve-month pace of +6.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
400.24M+10.1% QoQ
Last fiscal yearDec 2025
363.05M+13.4% YoY
LTMMar 2026
372.59M+6.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.5%——
1 year+13.4%——
3-year CAGR+29.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
363.05M USD
Year-over-year change
+13.4%
4-year CAGR
+25.7%

Weighted Avg Shares vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 weighted avg shares of 372.59M shares is the highest of the 11 companies compared; the peer median is 122.22M shares.
  • Its year-over-year change of +6.8% is the 6th highest of 11, against a peer median of +7.0%.
  • Over three fiscal years its annual growth of +29.9% compares with a peer median of +4.1%.
LXRX Competitors Peer median
Weighted Avg Shares for LXRX and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
MNKDMannKind CorporationLTM Mar 2026306.42M +8.4%+5.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
TRVITrevi Therapeutics, Inc.LTM Sep 2026151.86M +21.7%+31.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.8%+1.5%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding LXRX) 122.22M+7.0%+4.1%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue298K139K1.2M31.08M49.8M
Cost of Revenue55.05M52.52M58.97M616K274K
Gross Profit(54.75M)(52.38M)(57.77M)30.47M49.53M
Gross Margin-18371.8%-37681.3%-4798.0%98.0%99.4%
Research & Development55.05M52.82M58.89M84.48M61.12M
Selling, General & Admin000131.9M37.32M
Operating Expenses32.34M48.38M113.98M227.58M98.44M
Depreciation & Amortization292K427K554K534K621K
EBITDA(86.66M)(100.03M)(169.76M)(184.29M)(41.38M)
EBITDA Margin-29081.9%-71966.2%-14099.3%-592.9%-83.1%
Operating Income(87.09M)(100.76M)(171.75M)(197.12M)(48.91M)
Operating Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%
Interest Income134K1.6M7.73M12.29M6.91M
Interest Expense802K2.78M13.1M15.58M8.34M
Other Income / Expenses(668K)(1.18M)(5.37M)(3.29M)(1.43M)
Income Before Tax(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Pre-Tax Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
Income Tax Expense00000
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Net Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
EPS (Basic)(0.61)(0.62)(0.80)(0.63)(0.14)
EPS (Diluted)(0.61)(0.62)(0.80)(0.63)(0.14)
Weighted Avg Shares145.65M165.73M221.13M320.03M363.05M
Weighted Avg Shares (Diluted)145.65M165.73M221.13M320.03M363.05M

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.